Universe Pharmaceuticals INC(UPC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.45 | Insider Own | 89.18% | Shs Outstand | 0.6M | Perf Week | 10.43% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.5M | Perf Month | -7.26% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 1.3% | Short Float | 8.12% | Perf Quarter | 25.8% |
| Income | -0.00B | P/S | 1.23 | EPS this Y | - | Inst Trans | 87.43% | Short Ratio | 0.06 | Perf Half Y | 32.32% |
| Sales | 0.02B | P/B | 0.04 | EPS next 5Y | - | ROA | -2.55% | Short Interest | 0.04M | Perf YTD | 13.91% |
| Book/sh | 98.78 | P/C | 0.75 | EPS past 3/5Y | 82.27% - | ROE | -3.5% | 52W High | -75.84% ($17.96) | Perf Year | -16.28% |
| Cash/sh | 5.78 | P/FCF | - | Sales past 3/5Y | -23.66% -10.27% | ROIC | -3.36% | 52W Low | 117% ($2.00) | Perf 3Y | -99.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -100.01% | Gross Margin | 35.86% | Volatility(W/M) | 12.93% 8.7% | Perf 5Y | -99.95% |
| Dividend TTM | - | EV/Sales | 0.13 | Sales Y/Y TTM | -8.04% | Oper. Margin | -11.78% | ATR (14) | 0.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.75 | EPS Q/Q | 70.78% | Profit Margin | -10.95% | RSI (14) | 50.96 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.05 | Sales Q/Q | -1.28% | SMA20 | 2.76% ($4.22) | Beta | 1.75 | Target Price | - |
| Payout | - | Debt/Eq | 0.17 | Earnings | - | SMA50 | -4.99% ($4.57) | Rel Volume | 0.2 | Prev Close | $4.38 |
| Employees | 216 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | 12.09% ($3.87) | Avg Volume(3M) | 0.77M | Price | $4.34 |
| IPO | 2021/3/23 | Option/Short | No/Yes | Trades | 4143 | Volume | 155,374 | Change | -0.91% |
🌿 Manufacturer of herbal medicine derivatives. Health products for the elderly. A portfolio of cold remedies and longevity tonics. Distribution across 30 regions in China. Undergoing restructuring in 2025.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded less than usual. That is 20% of its average volume.
UPC has a sound balance sheet but weak earning power
Of every $100 in sales, $11.78 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $123. Peers typically go for $196.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.3%.
Tap to view numbers
It ranks #68 of 83 in the industry
Based on market cap of $22M.
SHPH#67 Shuttle Pharmaceuticals Holdings Inc $23M PER - UPC#68 Universe Pharmaceuticals INC $22M PER - 
TXMD#69 TherapeuticsMD Inc $21M PER - 
AYTU#70 Aytu BioPharma Inc $21M PER - 
OPTH#71 Optimi Health Corp $19M PER - 
FAQ
What kind of company is UPC?
UPC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of UPC?
The market cap of UPC is approximately $22M, ranking 5,199 within its sector.
What is the 52-week high and low for UPC?
UPC has recorded a 52-week high of $17.96 and a low of $2.00.
